Because it has been recently highlighted the importance of targeting different mechanisms in the tumor microenvironment using combination of drugs [40], we can speculate that anti-EGFR drugs in combination with anti-MAPK signalling agents or Jak-STAT inhibitors might more efficiently block the interaction between MSCs and breast cancer cells. Here, SOAT1 is linked to breast carcinoma.